Utilising CDX Mouse Models for Preclinical Studies in AML Research

TransCure bioServices has created cell line-derived xenograft (CDX) mouse models which will change the approach of researchers towards preclinical studies of cancer therapies for acute myeloid leukaemia (AML). With these models, researchers can obtain in-depth understanding of the efficacy and toxicity of AML treatments, ultimately resulting in the development of superior therapies and bringing optimism to the numerous patients diagnosed with AML annually.

Acute myeloid leukemia (AML) originates in the bone marrow and rapidly spreads throughout the bloodstream, affecting white and red blood cells as well as platelets. Standard mouse models are commonly used in preclinical studies to investigate AML therapies, but they cannot replicate human immune responses to the disease, which significantly influences its progression. Therefore, these models lack human-relevant efficacy when it comes to clinical trials. Moreover, due to the fast progression and acute nature of AML, inadequate mouse models struggle to accurately reflect its development. Furthermore, cancer cells spreading throughout the body pose challenges for monitoring preclinical treatment efficacy.

The latest mouse model for AML involves injecting AML luciferase tumour cell lines into mice, which permits the tracking of disease progression via bioluminescence imaging. By employing this model, researchers can now more effectively observe the in vivo behaviour of their AML therapies, while also acquiring a comprehensive understanding of the functional characterisation of AML pathogenesis.

More information online